Acurx Pharmaceuticals’ Ibezapolstat Is Proving To Be A Potential Treatment Game-Changer For C. Difficile Patients
Finding public companies that disrupt sectors often provide impressive returns. But, those changing a landscape by bringing to market products and services targeting unmet needs can deliver exponential ones. For most, finding the latter is the better choice. And Acurx Pharmaceuticals (NASDAQ: ACXP), a NASDAQ-listed biopharmaceutical company, is set up to deliver on the exponential side. That plan is in motion now starting a Phase2b trial this month to evaluate ibezapolstat to bring treatment relief to millions of patients suffering from C. difficile. The drug, by the way, is an excellent one. In fact, Phase 2a results were so impressive that an independent scientific review board agreed with a decision allowing ACXP to terminate its Phase2a trial early because of overwhelmingly positive data. · Small cap stocks · Investing ideas · Nasdaq ideas ...